Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Royce Laboratories' generic meperidine approved by FDA

July 8, 1997

MS&D discloses selective 5-HT1D agonists

July 8, 1997

AHP discloses agents useful for disorders of the dopaminergic system

July 8, 1997

Effects of befloxatone on psychomotor performance and memory in the elderly

July 7, 1997

Preliminary efficacy and safety studies with panamesine in schizophrenia

July 7, 1997

Duloxetine not different from placebo in double-blind depression study

July 7, 1997

Phase III trials show significant positive effect for sertindole on negative symptoms

July 7, 1997

Summary of perospirone clinical trials

July 7, 1997

Selective dopamine autoreceptor agonists prepared by American Home Products

July 7, 1997

SM-13496 preferentially affects mesocortical dopaminergic system

July 4, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...
How to Summit up? Dis-Harmoni on ivonescimab NSCLC phase III
BioWorld
Wall Street pundits were divided about the likely fate of ivonescimab, Summit Therapeutics Inc.’s bispecific antibody partnered with Akeso Pharmaceuticals Inc.,...